AbbVie Inc. has announced a quarterly dividend of $1.64, reflecting a nearly 6% increase, which affirms its commitment to shareholder value enhancement. With another FDA approval and a recent acquisition, AbbVie has cemented its reputation among investors who value dividend stocks for their potential for total return and steady passive income. AbbVie holds the distinction of being a 'Dividend King,' having increased its dividend for 52 consecutive years, showcasing stability and confidence in its financial performance. Since separating from Abbott Laboratories in 2013, AbbVie achieved a 12.5% compound annual growth rate in dividends, exceeding industry averages.
AbbVie has demonstrated a commitment to delivering consistently higher value to its investors, underscored by a quarterly dividend increase of nearly 6%.
For investors, dividends provide a reliable source of passive income while also enhancing the total return potential of their investment portfolios.
AbbVie stands as a Dividend King, having increased dividends annually for 52 years, a testament to its stability and dedication to shareholder returns.
Since its spinoff in 2013, AbbVie's dividend has seen a compound annual growth rate of 12.5%, setting it apart in the healthcare industry.
Collection
[
|
...
]